Bagley, Stephen J. http://orcid.org/0000-0002-7117-0539
Binder, Zev A. http://orcid.org/0000-0003-1158-231X
Lamrani, Lamia
Marinari, Eliana
Desai, Arati S.
Nasrallah, MacLean P. http://orcid.org/0000-0003-4861-0898
Maloney, Eileen
Brem, Steven http://orcid.org/0000-0002-5803-8920
Lustig, Robert A.
Kurtz, Goldie
Alonso-Basanta, Michelle
Bonté, Pierre-Emmanuel http://orcid.org/0000-0002-9732-5826
Goudot, Christel
Richer, Wilfrid
Piaggio, Eliane
Kothari, Shawn
Guyonnet, Lea
Guerin, Coralie L. http://orcid.org/0000-0002-1840-4017
Waterfall, Joshua J. http://orcid.org/0000-0002-3762-5050
Mohan, Suyash http://orcid.org/0000-0002-4025-115X
Hwang, Wei-Ting http://orcid.org/0000-0003-2829-2167
Tang, Oliver Y.
Logun, Meghan
Bhattacharyya, Meghna
Markowitz, Kelly
Delman, Devora
Marshall, Amy
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Amigorena, Sebastian http://orcid.org/0000-0001-8583-8416
Beatty, Gregory L.
Brogdon, Jennifer L.
Hexner, Elizabeth
Migliorini, Denis http://orcid.org/0000-0003-0151-3222
Alanio, Cecile http://orcid.org/0000-0003-2785-7445
O’Rourke, Donald M.
Funding for this research was provided by:
Novartis
Agence Nationale de la Recherche (ANR-21-RHUS-0016, ANR-10-EQPX-03, ANR-10-INBS-09-08)
Article History
Received: 29 April 2023
Accepted: 13 December 2023
First Online: 12 January 2024
Competing interests
: S.J.B. has received consulting fees from Kiyatec, Novocure and Bayer and has received research funding from Incyte, Tmunity, Novocure, GSK and Eli Lilly, all outside of the submitted work. S.J.B., A.S.D. and D.M.O. have inventorship interest in intellectual property owned by Novartis and the University of Pennsylvania: U.S. patent 62/809,245: “Combination therapies of EGFRvIII CARs and PD-1 inhibitors”. Z.A.B. has inventorship interest in intellectual property owned by the University of Pennsylvania and has received royalties related to CAR T-cell therapy in solid tumors. S.M. has received consulting fees from AI Integrated Radiological Solutions Medial and Qynapse SAS and has received research funding from Novocure and Galileo CDS, all outside of the submitted work. G.L.B. has received consulting fees from Seattle Genetics (now Seagen), Adicet Bio, Aduro Biotech, AstraZeneca, BiolineRx, BioMarin Pharmaceuticals, Bristol-Myers Squibb, Cantargia, Cour Pharmaceuticals, Boehinger Ingelheim, Genmab, Hibercell, HotSpot Therapeutics, Incyte Corporation, Janssen, Merck, Molecular Partners, NanoGhost, Pancreatic Cancer Action Network, Shattuck Labs and Verastem and reports receiving research funding from Incyte Corporation, Bristol-Myers Squibb, Verastem, Halozyme, Biothera, Newlink, Novartis, Arcus Biosciences and Janssen, all outside of the submitted work. E.J.W. receives honoraria and/or research support from BMS, Merck, MedImmune, Surface Oncology, Takeda and KyMab. E.J.W. has a patent licensing agreement for the PD-1 pathway. J.L.B. reports employment with, is a current holder of stock options and holds patents with Novartis Institutes for Biomedical Research. D.M. is inventor of patents in the field of cell and gene therapy filed by the University of Pennsylvania and the University of Geneva, is scientific co-founder of Cellula Therapeutics and is a member of the scientific advisory board of MPC, Limula and Cellula Therapeutics. D.M.O. has received consulting fees from Celldex Therapeutics, Prescient Therapeutics and Century Therapeutics; has received research funding from Celldex Therapeutics, Novartis and Tmunity Therapeutics; and is an inventor of intellectual property (U.S. patent numbers 7,625,558 and 6,417,168 and related families) and has received royalties related to targeted ErbB therapy in solid cancers previously licensed by the University of Pennsylvania. C.A. is a consultant for Biotherapy Partners. All other authors declare no competing interests.